Nuestros recursos

Many clinical trial sponsors don’t understand how decentralized clinical trials (DCTs) fit within today’s regulatory landscape. This lack of familiarity with decentralized research and regulatory approaches has created DCT hesitancy among sponsors.

ObvioHealth, a pioneering virtual research organization, announces the launch of a proprietary application programming interface (API) tailored specifically for digital therapeutic (DTx) clinical trials.

Patient engagement in clinical trials can make or break a study. Engaged patients are more likely to participate and complete studies, which can strengthen data collection and, ultimately, provide more robust therapeutic evidence of safety and efficacy.

Clinical trials lay the foundation for breakthrough drugs, digital therapeutics, and medical devices—and, at the center of these studies are the patients.

ObvioHealth and Sterling IRB today announce a partnership to help speed access and adoption of decentralized clinical trials. The partnership makes Sterling IRB the preferred Institutional Review Board for ObvioHealth.

In three short years, decentralized clinical trials (DCTs) have turned skeptics into believers. Trial sponsors who were once hesitant are now embracing the DCT model—and for good reason. Today’s DCTs are addressing longstanding industry challenges, expanding access to patients and clinicians, increasing diversity, accelerating cohort recruitment, and improving retention.

When it comes to decentralized clinical trials (DCTs), the pharmaceutical industry finds itself at a crossroads.